cnp520
Alzheimers Disease
Novartis PharmaceuticalsPhase 2/3Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 36/ 100
- Competitive Position
- 89/ 100
Competitive context
317 Active assets in the Alzheimers Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE Akiva Mintz | Phase 4 | BBB |
Namenda Carnot Laboratories | Phase 4 | BBB |
Cipralex NYU Langone Health | Phase 4 | BBB |
Rivastigmine Anhui Provincial Hospital | Phase 4 | BBB |
Sertraline AstraZeneca | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →